Lupus Research Alliance Celebrates FDA's Breakthrough Designation for Litifilimab: A Significant Step in Treating Cutaneous Lupus Erythematosus The Lupus Research Alliance hails FDA's Breakthrough Therapy status for Litifilimab, aiming to fast-track treatment for Cutaneous Lupus Erythematosus, impacting many lives.

Lupus Research Alliance Celebrates FDA's Breakthrough Designation for Litifilimab: A Significant Step in Treating Cutaneous Lupus Erythematosus #USA #New_York #Lupus_Research_Alliance #FDA_Designation #Litifilimab

iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations iRegene Therapeutics has received dual FDA recognitions for NouvNeu001—highlighting its potential to transform Parkinson's treatment with innovative cell therapy.

iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations #NouvNeu001 #FDA_Designation #iRegene_Therapeutics